Insulet shares data demonstrating Omnipod 5’s superiority to pump therapy

Insulet has announced positive results from a clinical trial showing improved glycemic and patient-reported outcomes in Type 1 diabetes with the Omnipod 5 automated insulin delivery (AID) system. Compared to non-automated insulin therapy.

Insulet’s Omnipod 5 was the first tubeless, wearable automated insulin delivery system cleared for marketing in the US.

The trial surveyed 194 adults in the U.S. and France who had Type 1 diabetes for at least one year, with HbA1c between 7% and 11%, and who had used traditional (non-AID) therapy. That included 87% using previous-generation Omnipod or Omnipod Dash systems.

Participants were split into two randomized groups: the control group (62 subjects) used their usual pump with Dexcom G6 CGM, while the intervention group (132 subjects) used Omnipod 5 with the G6.

Insulet reported that Omnipod 5 users showed a greater reduction in HbA1c (0.58%) difference, as well as a 17.5% improvement in time in range totalling an additional 4.2 hours per day. They saw a significantly lower mean glucose and time above 10mmols/L and also spent significantly less time below 3.9mmols/L.

To find out more, CLICK HERE.

Desang Diabetes Magazine is our free-to-receive digital journal (see below). We cover diabetes news, diabetes management equipment (diabetes ‘kit’ such as insulin pumps and continuous glucose monitoring equipment) and news about food suitable for a diabetic diet including a regular Making Carbs Count column. We just need your email address to subscribe you (it really is free, and you can easily unsubscribe should you wish to).

Sign me up!
Open publication
Buy a Desang kitbag

See our range of kitbags